Advertisement
Advertisement
U.S. markets open in 9 hours 4 minutes
Advertisement
Advertisement
Advertisement
Advertisement

DSS, Inc. (DSS)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.4089+0.0099 (+2.48%)
At close: 03:58PM EDT
0.4100 +0.00 (+0.27%)
After hours: 07:43PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Impact BioMedical Develops Quantum Antihistamine

    ROCHESTER, N.Y., July 26, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced that less than a year after successfully synthesizing its first Quantum-based compound, Impact Biomedical, Inc. and its research partner Global Research and Discovery

  • GlobeNewswire

    DSS Announces Licensing of Impact BioMedical’s Linebacker Portfolio to ProPhase Labs

    ROCHESTER, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced Global BioLife, Inc. (“Global BioLife”), a subsidiary of the Company’s wholly owned subsidiary Impact BioMedical, Inc. (“Impact BioMedical”), executed a license agree

  • GlobeNewswire

    DSS Strengthens and Expands Board with Appointment of Two Independent Directors

    ROCHESTER, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced the expansion of its Board of Directors with the appointment of two independent directors, Frankie Wong, a 20-year veteran of public-company financial reporting, and

Advertisement
Advertisement